clinical endpoint comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Soybean meal is used in food and animal feeds, principally as a protein supplement, but also as a source of metabolizable energy. Typically 1 bushel (i.e. 60 lbs. or 27.2 kg) of soybeans yields 48 lbs. (21.8 kg) of soybean meal. Most soybean meal is defatted, produced as a co-product of soybean oil extraction. Some, but not all, soybean meal contains ground soybean hulls. Soybean meal is heat-treated during production, to denature the trypsin inhibitors of soybeans, which would otherwise interfere with protein digestion.
== SI == si – (s) Sinhala language (ISO 639-1 code) Si – (s) Silicon SI (s) Slovenia (ISO 3166 and FIPS 10-4 country code digram) (i) Socialist International Sports Illustrated Système International (French, International System of Units) SIA – (s) Singapore Airlines (ICAO code) SIA – (i) Survivors of Incest Anonymous SIAM – (i) Society for Industrial and Applied Mathematics SIC – (a) Standard Industrial Classification SICS – (a/i) Swedish Institute of Computer Science SIDS – (a) Sudden infant death syndrome SIDU – (i) select, insert, delete, update. See Create, read, update and delete SIF – (i) Selective Identification Feature SIFF – (i) Successor IFF SIG (i) Schweizerische Industrie Gesellschaft (German, "Swiss Industry Company"). See also SIG Sauer, a firearms manufacturer spun off from the aforementioned company in 2000.
=== Antibiotics === Physicians often prescribe the antibiotic trimethoprim-sulfamethoxazole to prevent bacterial infections. This drug also has the benefit of sparing the normal bacteria of the digestive tract. Fungal infection is commonly prevented with itraconazole, although a newer drug of the same type called voriconazole may be more effective. The use of this drug for this purpose is still under scientific investigation.
Vosilasarm, also known by the development codes RAD140 and EP0062 and by the black-market name Testolone or Testalone, is a selective androgen receptor modulator (SARM) which is under development for the treatment of hormone-sensitive breast cancer. It is specifically under development for the treatment of androgen receptor-positive, estrogen receptor-negative, HER2-negative advanced breast cancer. Vosilasarm was also previously under development for the treatment of sarcopenia (age-related muscle atrophy), osteoporosis, and weight loss due to cancer cachexia, but development for these indications was discontinued. The drug is taken by mouth. Side effects of vosilasarm may include vomiting, dehydration, constipation, decreased appetite, weight loss, changes in sex hormone levels, elevated liver enzymes, and liver toxicity. Vosilasarm is a nonsteroidal SARM, acting as an agonist of the androgen receptor (AR), the biological target of androgens and anabolic steroids like testosterone and dihydrotestosterone (DHT). However, it shows dissociation of effect between tissues in preclinical studies, with agonistic and anabolic effects in muscle, agonistic effects in breast, and partially agonistic or antagonistic effects in the prostate gland and seminal vesicles. Vosilasarm was developed in 2010 and was first described in the literature in 2011. It was originally developed by Radius Health and is now under development by Ellipses Pharma.
Sources: en.wikipedia.org
=== Insulin glargine === Insulin glargine is a long-acting modified form of medical insulin used in the management of type 1 and type 2 diabetes. It is administered through subcutaneous injection. Its effects typically begin within an hour of injection. Common side effects include (hypoglycemia, issues at the injection site, itchiness, and weight gain. NPH insulin is generally preferred over insulin glargine during pregnancy. After injection, microcrystals gradually release insulin over a period of approximately 24 hours. This insulin works by facilitating the absorption of glucose by body tissues and reducing glucose production by the liver. Insulin glargine was patented, although the patent expired in most countries in 2014. It was approved for medical use in the United States in 2000. It is listed on the World Health Organization's List of Essential Medicines. In 2022, it ranked as the 28th most commonly prescribed medication in the United States, with more than 18 million prescriptions. In July 2021, the US Food and Drug Administration (FDA) approved an interchangeable biosimilar insulin product, Semglee (insulin glargine-yfgn), for the treatment of diabetes. Unbranded versions of insulin glargine and insulin glargine-yfgn are sold by Sanofi and Viatris.
=== Bile Acids === One of the key characteristics that distinguishes Clostridium scindens from other members of this genus is its ability to metabolize primary bile acids. Bile acids are cholesterol-based substrates formed in the liver, stored in the gallbladder, and released into the duodenum upon the entry of food to help facilitate the absorption of lipids and lipid-soluble vitamins. Humans naturally produce conjugated primary bile acids, such as cholic acid and chenodeoxycholic acid, after which gut commensals like C. scindens convert them into unconjugated secondary bile acids, like deoxycholic acid and lithocholic acid respectively. Primary bile acids are conjugated to either taurine or glycine by the enzyme N-acyltransferase to allow export from the liver.
Japanese forces in Vietnam surrendered on 15 August 1945, and an armistice was signed between Japan and the United States on 20 August. The Provisional Government of the French Republic wanted to restore its colonial rule in French Indochina as the final step of the Liberation of France. On 22 August, OSS agents Archimedes Patti and Carleton B. Swift Jr. arrived in Hanoi on a mercy mission to liberate Allied POWs, accompanied by French official Jean Sainteny. As the only law enforcement, the Imperial Japanese Army remained in power, keeping French colonial troops and Sainteny detained, to the benefit of the developing Vietnamese nationalist forces. The Viet Minh claimed that they, alongside Meo (Hmong) and Muong tribesmen, subdued the Japanese in a nationwide rebellion from 9 March to 19 August 1945, taking control of 6 provinces, although some of these claims are contested. Beginning with the August Revolution, Japanese forces allowed the Việt Minh and other nationalist groups to take over public buildings and weapons. For the most part, the Japanese Army destroyed their equipment or surrendered it to Allied forces, but some of the weapons fell to the Việt Minh, including some French equipment. The Việt Minh also recruited more than 600 Japanese soldiers to train Vietnamese. On 25 August, Ho Chi Minh persuaded Emperor Bảo Đại to abdicate and become "supreme advisor" to the new Việt Minh-led government in Hanoi. On September 2, aboard USS Missouri in Tokyo Bay, CEFEO Expeditionary Corps leader General Leclerc signed the armistice with Japan on behalf of France.
A vaccine is a biological preparation that provides active acquired immunity to a particular infectious or malignant disease. The safety and effectiveness of vaccines has been widely studied and verified. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the immune system to recognize the agent as a threat, destroy it, and recognize further and destroy any of the microorganisms associated with that agent that it may encounter in the future. Vaccines can be prophylactic (to prevent or alleviate the effects of a future infection by a natural or "wild" pathogen), or therapeutic (to fight a disease that has already occurred, such as cancer). Some vaccines offer full sterilizing immunity, in which infection is prevented. The administration of vaccines is called vaccination. Vaccination is the most effective method of preventing infectious diseases; widespread immunity due to vaccination is largely responsible for the worldwide eradication of smallpox and the restriction of diseases such as polio, measles, and tetanus from much of the world. The World Health Organization (WHO) reports that licensed vaccines are available for twenty-five different preventable infections. The first recorded use of inoculation to prevent smallpox (see variolation) occurred in the 16th century in China, with the earliest hints of the practice in China coming during the 10th century.
==== Warning signs ignored ==== From 2005 to 2006, an agent, Jiang Weisuo, from Shaanxi Jinqiao Dairy Company in northern China reportedly publicly discussed his fears about unauthorised substances being added to competitors' milk. His complaints to regulators and dairy makers in 2005 and 2006 never yielded any result; his story was picked up by China Central Television, who ran a report, complete with footage of adulteration in progress, yet the Shaanxi Quality and Technical Supervision Bureau said they failed to find evidence of wrongdoing. The bulletin board of the Administration of Quality Supervision, Inspection and Quarantine (AQSIQ) indicated a rare occurrence of kidney stones in children–all causally traced to Sanlu milk formula–was flagged by at least one member of the public in June 2008 and by a urologist in a paediatric hospital on 24 July 2008. Neither received definitive replies. The paediatrician, who specifically asked the AQSIQ to refer his observations to epidemiologists, was asked to refer his query to the health department. In June, Jiangsu media reported a two-month surge in the number of babies diagnosed with kidney disease; in July, a parent of a sick baby in Hunan questioned Sanlu's powdered milk and complained to the AQSIQ. Gansu Province sent a report to the Ministry of Health on 16 July to alert that one local hospital had identified an increase in the incidence of kidney ailments among babies in the months earlier, and that most victims had consumed Sanlu's baby formula. The health ministry sent investigators to Gansu in early August.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.